Diabetes, antidiabetic medications and risk of dementia: A systematic umbrella review and meta‐analysis
Authors' conclusion
Metformin, thiazolidinediones, pioglitazone, GLP1RAs and SGLT2is were associated with reduced risk of dementia. More longitudinal studies aimed at determining their relative benefit in different populations should be conducted.
Study context
- Population
- Individuals with diabetes; reviews searched until 2 July 2023100 reviews, 27 cohort/case-control studies
- Participants
- 3,046,661 individuals
- Comparison
- Antidiabetic medications and risk of dementia
- Outcome
- Risk of dementia
Methodological detailsrandom-effects meta-analyses, cohort/case-control studies, Risk of bias assessed with AMSTAR tool and Newcastle-Ottawa Scale
- Random-effects meta-analyses
- Cohort/case-control studies
- Risk of bias assessed with AMSTAR tool and Newcastle-Ottawa Scale
Pooled result
As reported in the abstract
- Metformin, thiazolidinediones, pioglitazone, GLP1RAs and SGLT2is associated with significant reduction in risk of dementia
- No significant effect for DPP-4i, α-glucosidase inhibitors or insulin
- Meglitinides and sulphonylureas associated with increased risk
Further pooled results
Metformin by country and world region
- By country, only significant effect for the United States
- Significant in Western but not Eastern populations
Original publication
Diabetes, antidiabetic medications and risk of dementia: A systematic umbrella review and meta‐analysis. Diabetes Obes Metab. Published 23 October 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →